Nls pharmaceutics to proceed with phase 3 clinical program (amaze) for mazindol er for the treatment of narcolepsy following fda review and irb approval of the full study protocol

ZÜrich, switzerland / accesswire / july 3, 2023 / nls pharmaceutics ltd. (nasdaq:nlsp)(nasdaq:nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that the u.s. food and drug administration (fda) has reviewed the full protocol for the nls-1031 study, part of the phase 3 program for mazindol er, called amaze.
NLSP Ratings Summary
NLSP Quant Ranking